Manuscript accepted on :December 17, 2016
Published online on: --
The Effect of Atrovastatin on the Ovarian Arterial Blood Flow and Serum Androgen Level in PCOS Patient
Maryam Akbari1*, Alireza Almasi2 , Zahra Naderi3 , Jalil Kouhpayezadeh4 , Roghaye Pourali1 and Zohreh Hossinzadeh5
1Shahid Akbar Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran.
2Department of Radiology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
3Department of Midwifery and Gynecology, Shahid Akbar Abadi Hospital, Iran.
4Department of Social Medicine, Medicine College, Iran University of Medical Sciences, Tehran, Iran.
5Neonatal Intensive Care Nursing, Tehran University of Medical Sciences , Tehran, Iran.
*Corresponding Author E-mail: email@example.com
Various researches have been conducted over the recent years on the therapeutic effects of statins on the metabolic and hyper-androgenic state of the patients suffering from PCOS. The present research seeks to evaluate the treatment with atorvastatin and its effect on the lipid profile level, serum androgen status and morphology and blood flow of polycystic ovaries. A double blind clinical trial was designed for this research where the women with PCOS resorting to the gynecology clinic of Firouzgar Hospital were randomly divided into two groups: case and Control . Early at the beginning of the research, variables such as body mass, lipid profile, blood androgen level, fasting blood Sugar , size of the ovary, and resistance of the stromal artery of ovary were studied. For a period of 6 weeks, one group was given with a daily dose of 40 mg atorvastatin, while the other group just received placebo. All the variables were studied once again after 6 weeks and the results were analyzed using SPSS v.16. The case group included 20 patients suffering from PCOS who received atorvastatin, while there were 20 patients with PCOS in the witness group who just received placebo. The average ages in the atorvastatin and placebo groups were 27.7 ± 3.41 and 9.30 ± 4.8 years old respectively. A significant difference was observed between the two groups in terms of changes in the average cholesterol and LDL levels before and after the intervention. This reduction was more significant in the atorvastatin group. After prescription of atorvastatin, the level of Androstenedione had decreased significantly in treatment group. A statistically significant reduction was observed in the size of left and right ovaries in the group receiving atorvastatin. No significant changes were observed in the size of the ovaries in the group receiving placebo. The average arterial resistance level of left and right ovaries before and after intervention in atorvastatin group exhibited a significant reduction. Having discarded the confounding effect of RI, this difference with the witness group was statistically significant. Keeping in mind the effects of atorvastatin such as improving the lipid profile status and reduction of androstenedione among those with PCOS, it can be used as an auxiliary treatment to control symptoms and long-term side effects among patients. Considering the shrinkage of ovary size and enhancement of blood flow to PCOS ovary, future researches can focus on effectiveness of statins in improving the ovulation status of performance of PCO ovaries.
Hyper-androgenism, Arterial Performance of Ovary, Hyperinsulinemia, Atorvastatin. PCOSDownload this article as:
|Copy the following to cite this article:
Akbari M, Almasi A, Naderi Z, Kouhpayezadeh J, Pourali R, Hossinzadeh Z. The Effect of Atrovastatin on the Ovarian Arterial Blood Flow and Serum Androgen Level in PCOS Patient. Biomed Pharmacol J 2016;9(3).
|Copy the following to cite this URL:
Akbari M, Almasi A, Naderi Z, Kouhpayezadeh J, Pourali R, Hossinzadeh Z. The Effect of Atrovastatin on the Ovarian Arterial Blood Flow and Serum Androgen Level in PCOS Patient. Biomed Pharmacol J 2016;9(3). Available from: http://biomedpharmajournal.org/?p=11756
Polycystic ovary syndrome is a syndrome with various symptoms and signs. It is also the most common endocrine pathology among women observed during the ages of fertility, but it is far from being exclusive and hence no particular cause can be introduced for it (1). Various definintoin have been proposed for this syndrome. According to Rotterdam criteria, the presence of 2 of these 3 symptoms indicates this syndrome: 1. no or little ovulation (Oligomenorrhea or Amenorrhea), 2. hyper-androgenomia or hyper-androgenism, and 3. polycystic ovaries (diagnosed through sonography and through discarding other complications with too much discharge of androgen or correlating complications) (1). Nearly 70% of polycystic ovary syndromes exhibit signs of the abnormal lipid levels in body (2). Women with PCOS whether fat or not exhibit degrees of Dyslipidemia and these changes are observed in all three levels of TG, HDL, and LDL (3). As various researches have shown, further to reducing the lipid level of blood, atorvastatin also helps decrease androgen (4). In this syndrome, there is a direct correlation between levels of androgen and insulin resistance and blood lipids level. Reducing the lipid level of blood can help improve the androgen level and enhance Hyperinsulinemia and reduce the side effects of this disease (4). Various researches have also pointed to the fact that atorvastatin can help improve the blood flow of Brachial artery (1). Although no studies have ever been conducted on this medicine and blood flow of ovary artery, we have set to study the effect of this medicine on ovary artery given the available literature indicating improvement of DOMINANT ovary and ovulation with the rise and enhancement of blood flow of ovary artery (5). Considering the problems of those with this disease (obesity, hyperinsulinemia, hyper-androgenomia, no ovulation and Hirsutism), it is necessary to seek an appropriate cure to this disease and try to enhance the life quality of these patients.
Material and Method
This is an analytical, double blind, clinical trial research. The population includes all the women with PCOD resorting to the clinic of Firouzgar Hospital from November 2004 to March 2005. The patients and the measurers had no idea of the variables associated with attribution of the patients. The following i